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Lymphatic System
The lymphatic system consists of lymph nodes, spleen, thy-
mus, bone marrow, digestive system lymphatic tissue, and
lymphatic vasculature. The main functions of the lymphatic
system are production of immune cells, collection, and
transportation of extravasated fluid and macromolecules
fromperipheral tissues, filtering lymphatic fluid, and removal
of foreign material.1 The lymphatic capillaries in the periph-
eral tissues merge with larger collecting lymphatic vessels,
specialized for the transport of large volumes of lymph, that
in turn connect with chains of lymph nodes.1 Lymphatic
vessels are typically found in all vascularized tissues, with
the notable exception of bone marrow and the central
nervous system.2 From an immunological point of view,
lymph nodes are strategically positioned patrol stations for
antigens from peripheral tissues.3 Naïve lymphocytes circu-
late through lymph nodes.When a foreignmicrobe enters the
skin, dendritic cells (DCs) and macrophages phagocytose the
invading microbes and migrate to lymph nodes via lymph
vessels. To elicit an adaptive immune response, DCs must
interact with antigen-specific T-cells and B-cells in the lymph
node and present the foreign antigens.3 Intruders, such as
bacteria and tumor cells, have also learned to take advantage
of the vast lymphatic network to facilitate their spreading and
growth. Thus, lymphatic vessels and lymph nodes are in-
volved in several human diseases, such as lymphedema,
inflammation, and tumor metastasis.
Lymphedema
Malfunction of the lymphatic system leads to chronic lymph-
edema that is characterized by gross swelling of the affected
peripheral area, commonly the limbs. As the disease pro-
gresses, edema is accompanied by fibrosis and in the late
stage of the disease replaced by fibrosis and adipose tissue.4
Lymphedema patients are susceptible to infections as a result
of encouragedmicrobial growth due to extravasated fluid and
proteins and an impaired local immune response.5 Many
patients need constant prophylactic antibiotics because of
recurrent erysipelas and other soft tissue infections. Chronic
neuropathic pain is also a common symptom.
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Abstract Lymphedema is a progressive disease caused by damage to the lymphatic network.
Recent development in the fields of preclinical growth factor research and lymphedema
microsurgery promise new hope for lymphedema patients. In this article, we review the
latest results on basic research and highlight the role of specific growth factors in normal
lymphatic development and several disease states. Lymph node transfer, a new
promising method in reconstructive lymphatic microsurgery, is also dependent on
the lymphatic vascular regrowth and lymphangiogenic growth factors. We discuss the
scientific basis of lymph node transfer and therapeutic potential of lymphangiogenic
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Lymphedema develops after damage of the lymphatic
network due to infections, surgical or radiation therapy of
metastatic cancer or trauma. Rare hereditary forms of lymph-
edema are caused by structural defects in the lymphatic
vessels.6 A globally remarkable cause of lymphedema is
filariasis, which affects more than 90 million people.5 It has
been estimated that currently several million patients suffer
from acquired lymphedema in the United States alone.7 The
effective treatment of cancer often requires removal of
regional lymph nodes and the associated collecting lymphatic
vessels to eradicate metastases. This leads to a disruption of
the lymphatic flow in the operated area, which may result in
chronic lymphedema of the affected limb. Approximately 10
to 30% of breast cancer patients develop lymphedema after
axillary dissection.8–10
The treatment of lymphedema is currently based on
compression garments and physiotherapy. Occasionally sur-
gical treatment options including liposuction,11 lymph node
transfer,12 and lymphaticovenous or lymphaticolymphatic
shunts5,13–15 are used. These surgical treatment options are
described in other review articles of this special lymphedema
theme issue.
Regulation of Lymphangiogenesis
Lymphatic Vessel Differentiation during
Embryogenesis
The development of lymphatic vessels begins in the embryo
at midgestation, at a time when the cardiovascular system is
established and fully functional. The homeobox transcription
factor Prox1 is essential for the establishment of the identity
of the lymphatic endothelial cells.16 Prox1 is also important
for maintenance of the lymphatic vasculature during later
stages of development and in adulthood as Prox mice
develop chylous ascites, abnormal lymphatic vessels and
adult-onset obesity.17 After the lymphatic vascular differen-
tiation process, vascular endothelial growth factor C (VEGF-C)
is crucial for the further growth of the lymphatic vasculature,
a process called lymphangiogenesis.18
Importance of VEGF-C/D for Lymphatic Vascular
Growth
VEGFs are themost specific and important regulators of blood
and lymph vessel growth, also termed angiogenesis and
lymphangiogenesis.19,20 They stimulate cellular responses
by binding to the tyrosine kinase receptors VEGFR-1,
VEGFR-2, and VEGFR-3, which are specifically expressed on
blood and lymphatic endothelial cells. VEGFR activation
promotes cell proliferation, migration and survival.21 VEGF-
A binds to VEGFR-1 and VEGFR-2 and induces mainly angio-
genesis while VEGF-C and VEGF-D bind VEGFR-3 and induce
mainly lymphangiogenesis.2,21 By targeting VEGFR-3 in the
lymphatic endothelial cells VEGF-C and VEGF-D are the most
important and specific lymphatic vessel growth factors
known.22 VEGF-A seems to stimulate mainly circumferential
hyperplasia of lymphatic capillaries, and only indirectly
lymphangiogenesis via the recruitment of inflammatory
cells.23 Several other (unspecific) growth factors such as
fibroblast growth factor-2, insulin-like growth factor 1
(IGF-1), IGF-2, hepatocyte growth factor, endothelin-1, and
platelet-derived growth factor subunit B have been reported
to induce lymphangiogenesis in various situations. Most of
these effects are associated with the induction of VEGF-C and
VEGF-D in a variety of cell types including inflammatory cells
and fibroblasts.1,24 VEGFs also have coreceptors including
neuropilin (Nrp)-1 and Nrp-2, certain integrins, as well as
heparan sulfate proteoglycans, which modulate the signaling
of VEGF receptors and provide specificity for their signal
transduction.20,25,26
Factors Regulating Lymphatic Vessel Valve Formation
The forkhead transcription factor Foxc2 is highly expressed in
the developing lymphatic vessels and also in lymphatic valves
in adults.27 The initial development of lymphatic vasculature
proceeds normally in the absence of Foxc2, but at later stages
of embryogenesis lymphatic vessels are severely affected.27
Recently, transcription factors, Prox1 and Foxc2, were shown
to cooperate and control connexin37 and calcineurin during
lymphatic valve development.28Mutation in Foxc2 causes the
hereditary lymphedemadistichiasis syndrome.29 Interesting-
ly,mutations of connexin47 have been shown to be associated
with increased risk of secondary lymphedema after breast
cancer treatment.30
Tumor-Associated Lymphangiogenesis
Lymph node metastasis is an important prognostic indicator
in many tumor types.31 Tumor cells can invade either pre-
existing lymphatic vessels or new lymphatic vessels formed at
the tumor periphery by tumor-induced lymphangiogenesis.
Many types of tumors express the lymphangiogenic growth
factors VEGF-C and VEGF-D, and several studies have shown
that expression of these growth factors actively induces
tumor-associated lymphangiogenesis, leading to lymphatic
invasion, lymph node and distant metastasis, and subse-
quently to poor patient survival.32 Also, tumor-associated
macrophages have been shown to express VEGF-C and
VEGF-D and contribute to peritumoral lymphangiogenesis.33
In mouse models, blockage of VEGFR3 signaling inhibits
lymphatic metastases (reviewed by Alitalo et al1).
Lymphatic Vessel and Inflammation
Lymphatic vessels proliferate during inflammation. Macro-
phages have been shown to produce VEGF-C and contribute
to lymphatic regeneration after tissue transfer.34 In a mouse
diabetes (db/db) model, injection of IL1-β stimulated db/db
macrophages to diabetic wounds induced lymphatic vessel
formation and accelerated wound healing.35 Furthermore,
newly formed lymphatic vessels expressed both macrophage
marker F4/80 and lymphatic marker LYVE-1 suggesting that
new lymphatic vessels were formed from F4/80 cells, namely,
macrophages.35 IL-1α, IL-1β, and TNF-α have been shown to
induce VEGF protein and VEGF-C mRNAs in human lung
fibroblasts.36 IL-1β induces expression of VEGF-C at the
transcriptional level.37 High levels of lymphangiogenic fac-
tors are also produced by macrophages and granulocytes in
inflamed tissue, and blocking these factors suppresses
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lymphangiogenesis and reactive inflammation of the lymph
node.38 On the other hand, soft tissue infections and inflam-
mation also play a role in the development of lymphedema, as
nonsteroidal anti-inflammatory drugs have been shown to
affect lymphedema development.39 However, the exact mo-
lecular mechanisms of this process are not fully understood.
Also, lymphedema patients are susceptible to infections as a
result of encouraged microbial growth due to extravasated
fluid, proteins, and an impaired local immune response.5
Lymphatic Vascular Growth after Surgical Lymph Node
Transfer
Lymph node transfer, introduced by Becker, is a fairly new
promising technique that aims to rebuild the lymphatic vas-
cular anatomy after surgical treatment of metastatic cancer
(see separate review by Becker in this JRM issue). However,
lymphatic anastomoses in this technique are expected to form
spontaneously. Thus, the outcome of this treatment relies on
the spontaneous lymphatic regrowth (lymphangiogenesis) in
the axillary area. Patel et al documented the integration of
distally placed lymphnodeflapsusing indocyaninegreen (ICG)
lymphography and showed ICG uptake in all the flaps as a sign
of integration.40 Interestingly, we have recently shown, that
human lymph nodes express VEGF-C, which provides a scien-
tific explanation for this technique.41 The therapeutic effect of
this surgical method has been tested in different experimental
lymphedema animal models and recently also in human
lymphedema patients.12,41–43 In patients, lymphatic tissue
can be harvested as a vascularized free flap from the lower
abdominal wall and transferred into the axilla (see ►Fig. 1A).
All clinical studies have also shown an improvement of skin
infections (erysipelas, lymphangitis, and cellulitis) after lymph
node transfer.
As we are operating on patients that have previously
developed lymphedema symptoms in their upper extremities
we need to be extremely careful with the donor site morbidi-
ty. Harvesting lymph nodes from the lower abdominal wall
seems to induce seroma formation12,42 but so far there are no
reports on lymphedema symptoms of the lower limb after the
lymph node transfer surgery. In our patient material postop-
erative lymphoscintigraphy revealed minor subclinical
changes in the lymphatic flow of the donor site limbs in 6
out of 10 patients. However, none of the patients had changes
in their lower limb circumferences during the 8- to 56-month
follow-up.44
Lymphangiogenic Therapy
In the lymph node transfer technique the lymphatic vascular
anastomoses are expected to form spontaneously. Clinical and
experimental data however suggests that even though spon-
taneous lymphangiogenesis after lymph node transfer does
occur, the incorporation of the transferred lymph nodes into
the existing lymphatic network may fail.12,42,45,46 This poor
incorporation efficiency may compromise the outcome of the
operation, because connection with lymphatic vessels is re-
quired for maintenance and function of the lymph nodes.46,47
Results from the preclinical lymphedema models employ-
ing VEGF-C or VEGF-D gene transfer48–52 or application of
recombinant protein53,54 have demonstrated the potential
and specificity of these factors for inducing growth of new
lymphatic vessels. The short half-life of the VEGF proteins
favors the use of transient gene transfer as a mode of
treatment.55 First experimental lymphedema animal models
focused on regrowth of new lymphatic capillary vessels in
response to lymphatic growth factor therapy.50–52 Together
with other groups we havemore recently shown that also the
collecting lymphatic vessels can be rebuilt with the VEGF-C/D
therapy.45,46,54 Adenoviral VEGF-C or VEGF-D gene transfer
results into transient lymphatic vessel growth factor over-
expression in the targeted area.45,46,50 During the first
2 weeks robust growth of lymphatic vessels can be detected
but after 2 weeks, as the adenoviral growth factor expression
is downregulated, the lymphatic vessel network regresses.50
However, the newly formed vessels that have lymphatic flow
seem to stabilize and maturate into collecting lymphatic
vessels spontaneously over the course of 6 months.46 Thus,
the growth factor stimulated vessels seem to engage an
intrinsic differentiation andmaturation program into collect-
ing lymphatic vessels.
Combining Lymphangiogenic Growth Factor
Treatment with Lymph Node Transfer
Lymph nodes need lymphatic flow to remain functional.45–47
Without connectionswith the afferent and efferent lymphatic
vessels lymph nodes will regress.47 The idea of combining
growth factor treatment with the lymph node transfer as a
Fig. 1 Future vision on how to reconstruct the lymphatic vascular
anatomy of the axilla after axillary lymph node dissection and oncol-
ogic cancer treatment. (A) Lymphatic tissue from the lower abdominal
wall can be harvested as a vascularized free flap. (B) Adenoviral vector
encoding vascular endothelial growth factor C (VEGF-C) is injected into
the distal edges of the lymphatic flap to enhance lymphangiogenesis
and further lymphatic network maturation. (C) VEGF-C treated lym-
phatic flap is placed into the axilla to replace the removed scar tissue.
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lymphedema treatment was first presented by Tammela
et al.46 The results of this study showed that the sentinel
node function of transferred lymph nodes was regained and
intracutaneously injected lung carcinoma cells were trapped
in the transferred lymphnode.46 Previously it has been shown
that transplanted lymph nodes retain the ability to mount a
cytotoxic immune response against tumor cells and that they
recover a normal architecture.46,47,56,57
More recently the efficacy of the VEGF-C and -D growth
factor therapies and lymph node transfer was also tested in
a lymphedema large animal model.45,54,58 Postoperative
lymphatic drainage was significantly improved in the
VEGF-C/D–treated animals comparedwith controls. Impor-
tantly, the structure of the transferred lymph nodes was
best preserved in the VEGF-C–treated animals.45,58
Control-treated lymph nodes regressed and their follicular
structure was replaced by adipose and fibrotic tissue. This
is in concordance with previous data, which indicate that
the lymph nodes need lymphatic vasculature and exposure
to lymph flow to remain intact.46,47 Perinodal VEGF-C
injection induces less inflammatory macrophage deposi-
tion and lymph node lymphangiogenesis compared with
intranodal VEGF-C.58
Future Perspectives and Conclusions
Approximately, 200,000 new cases of breast cancer are
diagnosed annually in the United States alone. Besides breast
cancer, many other cancer types spread via the lymphatic
vessels necessitating regional surgery of the lymph nodes
and making a large patient population susceptible to the
development of lymphedema. Recent data suggests that
some of the patients onwhomwe operatemay be genetically
predisposed to develop lymphedema symptoms after any
surgical operation—cancer operation or microvascular flap
operation.30
Lymph node transfer is a new technique in lymphedema
surgery. In our patientmaterial, 10 to 20% of all postmastectomy
patients who ask for breast reconstruction also have lymphede-
ma symptoms of the upper arm. The fact that lymph node
transfer can easily be performed in combination with routine
microvascular breast reconstruction has made this method
attractive.12,42,59 However, the lack of randomized clinical trials
and the methodological variance in the published studies still
leave open questions about the efficacy of the lymph node
transfer surgery.60 To truly show the efficacy of this new
technique we need results from large clinical studies and differ-
ent units. According to our ownexperience, not all patients seem
to benefit from the lymph node transfer surgery. This might be
partly explained by the differences in lymph node VEGF-C
expression. Recent findings from the experimental animalmod-
els clearly favor the use of growth factors in conjunction with
lymph node transfer to augment incorporation of the grafted
lymph node into the resident lymphatic vascular tree.45,46,58
Vectors inducing short-termoverexpression of the patients’own
endogenous lymphatic growth factors in the distal edge of the
lymphatic tissue flap could be used to enhance the therapeutic
effect of lymph node transfer technique (►Fig. 1).
VEGF-C and -D are also involved in lymphaticmetastasis of
several human tumors and therefore patient safety is an
important issue. However, human lymph nodes also produce
endogenous VEGF-C and lymph node transfer is already used
in cancer patients.42 In experimental models newly formed
lymphatic vessels seem to stabilize after the short-term
(1 week) VEGF-C overexpression.45,46,58 Thus, long lasting
lymphatic growth factor therapy is not needed.
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